NMRA - Neumora Therapeutics, Inc.

QQQ $ 589.60 $ 4.40 (0.75 %)

DIA $ 462.45 $ 5.05 (1.1 %)

SPY $ 658.47 $ 6.50 (1 %)

TLT $ 89.50 $ 0.27 (0.3 %)

GLD $ 373.70 $ -0.58 (-0.15 %)

Previous Close

$ 2.33

Open

$ 2.35

Bid

$ 2.32 x 867

Ask

$ 2.33 x 393

Day's Range

$ 2.29 - $ 2.41

52 Week Range

$ 0.61 - $ 11.57

Volume

679,907

Average Volume

Market Cap

389.32M

Beta (5Y Monthly)

$ 2.17

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-06-2025	09-30-2025	10-Q
2	08-06-2025	06-30-2025	10-Q
3	05-12-2025	03-31-2025	10-Q
4	03-03-2025	01-01-1970	10-K
5	11-12-2024	09-30-2024	10-Q
6	08-06-2024	06-30-2024	10-Q
7	05-07-2024	03-31-2024	10-Q
8	03-07-2024	12-31-2023	10-K
9	11-01-2023	09-30-2023	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Stifel Maintains Hold on Neumora Therapeut...
11/17/2025 13:52:02

Stifel analyst Paul Matteis maintains Neumora Therapeutics (NASDAQ:NMRA) with a Hold and raises the price target from $2 to $3.

Neumora Therapeutics Q3 EPS $(0.35) Misses...
11/06/2025 12:22:03

Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate o...

Needham Maintains Buy on Neumora Therapeut...
10/28/2025 11:41:50

Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and raises the price target from $6 to $8.

Guggenheim Upgrades Neumora Therapeutics t...
10/27/2025 12:20:25

Guggenheim analyst Yatin Suneja upgrades Neumora Therapeutics (NASDAQ:NMRA) from Neutral to Buy and announces $14 price target.

12 Health Care Stocks Moving In Monday's P...
10/27/2025 12:06:22

Neumora Begins Phase 1 Trial for New Schiz...
10/27/2025 11:11:40

Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, ...

Neumora Announces Preclinical Data For NMR...
10/27/2025 10:36:00

NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstr...

12 Health Care Stocks Moving In Thursday's...
10/23/2025 17:07:13

This Warner Bros. Discovery Analyst Is No ...
09/16/2025 14:02:18

JP Morgan Downgrades Neumora Therapeutics ...
09/16/2025 10:39:12

JP Morgan analyst Tessa Romero downgrades Neumora Therapeutics (NASDAQ:NMRA) from Neutral to Underweight.

Neumora Therapeutics Q2 EPS $(0.33) Beats ...
08/06/2025 20:51:16

Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

12 Health Care Stocks Moving In Monday's A...
07/28/2025 21:05:57

boston-beer-posts-better-than-expected-earnings-joins-scholastic-deckers-outdoor-saia-and-other-big-stocks-moving-higher-on-friday

Boston Beer Posts Better-Than-Expected Ear...
07/25/2025 14:31:45

12 Health Care Stocks Moving In Friday's I...
07/18/2025 17:06:16

Mizuho Maintains Outperform on Neumora The...
07/16/2025 12:19:13

Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and raises the price target ...

Neumora Therapeutics Begins Phase 1 Clinic...
07/09/2025 11:08:05

NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profileNo convulsions observed...

12 Health Care Stocks Moving In Monday's A...
05/19/2025 21:05:52

On May 14, Neumora Therapeutics Received N...
05/16/2025 20:45:25

-SEC Filing

Needham Reiterates Buy on Neumora Therapeu...
05/13/2025 13:44:48

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $5 price target.